🇺🇸 FDA
Pipeline program

DX-88 (ecallantide)

DX-88/5

Phase 2 small_molecule completed

Quick answer

DX-88 (ecallantide) for Hereditary Angioedema (HAE) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hereditary Angioedema (HAE)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials